CoChat

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

Open access
Jensterle, Mojca, Herman, Rok, Janež, Andrej · 2022 · Biomedicines

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Abstract

Despite the continuous effort to understand the pathophysiology and determine potential therapeutic targets, PCOS treatment largely depends on lifestyle intervention and symptomatic management of individual signs and symptoms. International guidelines recognize the importance of weight reduction as a cornerstone for the achievement of better metabolic, reproductive, and cardiovascular outcomes in PCOS women who are overweight or obese. With its profound weight loss potential in patients with or without diabetes, the administration of GLP-1 receptor agonists has been investigated in overweight/obese women with PCOS in several single-center randomized control trials with considerable variation in the dosing regimen, follow-up duration, and outcome measurements over recent years. Most trials reported superior weight loss effects of GLP-1 receptor agonists compared to lifestyle changes or metformin, with additional metabolic, reproductive, and cardiovascular benefits in this population. However, their use is currently not widely accepted by the clinical community that treats this population. The major concern is how to balance the reproductive and metabolic treatment strategies since the use of GLP-1 receptor agonists requires effective contraception while on therapy and a washout period before pregnancy. Both approaches are not mutually exclusive, yet the best choice requires a careful assessment of the clinical context. Knowing a patient’s individual circumstances, precise clinical sub-phenotyping, and regular monitoring are crucial components for the safe and effective use of these new tools. In the present narrative review, we explore the current clinical evidence and provide the future perspectives and challenges for their implementation in PCOS management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines10081989

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The potential position of GLP-1RAs in the PCOS treatment process and their mechanism of action. The high-level evidence for GLP-1RAs as anti-obesity medications is provided for populations with obesity with or without diabetes. The assessment of PCOS-specific symptom-centric treatment outcomes require future randomized control trials with well-characterized sub-phenotyping of the included cohorts. Legend: GLP-1RAs—Glucagon-like peptide-1 receptor agonists, IVF—In vitro fertilization.
Figure 1 The potential position of GLP-1RAs in the PCOS treatment process and their mechanism of action. The high-level evidence for GLP-1RAs as anti-obesity medications is provided for populations with obesity with or without diabetes. The assessment of PCOS-specific symptom-centric treatment outcomes require future randomized control trials with well-characterized sub-phenotyping of the included cohorts. Legend: GLP-1RAs—Glucagon-like peptide-1 receptor agonists, IVF—In vitro fertilization.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 85 references

Cited by

See all 50

Metadata

Authors
Jensterle, M., Herman, R., & Janež, A.
Affiliations
University of Ljubljana (SI)
Corresponding author
Janež, Andrej
Venue
Biomedicines
Publisher
MDPI AG
Published
2022-08-16
Volume
10
Issue
8
Pages
1989
ISSN
2227-9059 (ISSN-L)
OpenAlex
W4292263170
Cited by
50
References
85
Citations by year
2026: 9 · 2025: 21 · 2024: 7 · 2023: 12 · 2022: 1
FWCI
1.65
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
polycystic ovary syndrome, GLP-1 receptor agonists, weight loss, obesity, metformin, contraception, cardiovascular outcomes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives. https://app.cochat.ai/papers/10.3390/biomedicines10081989
The paper
Jensterle, M., Herman, R., & Janež, A. (2022). Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives. Biomedicines. https://doi.org/10.3390/biomedicines10081989

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.